Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study-Reference-Cited by-同舟云学术

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Published:2015-09 Issue:9 Volume:16 Page:1025-1036
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Ravandi Farhad,Ritchie Ellen K,Sayar Hamid,Lancet Jeffrey E,Craig Michael D,Vey Norbert,Strickland Stephen A,Schiller Gary J,Jabbour Elias,Erba Harry P,Pigneux Arnaud,Horst Heinz-August,Recher Christian,Klimek Virginia M,Cortes Jorge,Roboz Gail J,Odenike Olatoyosi,Thomas Xavier,Havelange Violaine,Maertens Johan,Derigs Hans-Günter,Heuser Michael,Damon Lloyd,Powell Bayard L,Gaidano Gianluca,Carella Angelo-Michele,Wei Andrew,Hogge Donna,Craig Adam R,Fox Judith A,Ward Renee,Smith Jennifer A,Acton Gary,Mehta Cyrus,Stuart Robert K,Kantarjian Hagop M

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Prognostic index for adult patients with acute myeloid leukemia in first relapse;Breems;J Clin Oncol,2005

2. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia;Roboz;J Clin Oncol,2014

3. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial;Faderl;J Clin Oncol,2012

4. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia;Ferrara;Haematologica,2004

5. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry;Juliusson;Blood,2009

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial;Blood Neoplasia;2024-06

3. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study;Leukemia & Lymphoma;2024-05-07

4. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial;Blood Advances;2024-04-23

5. Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies;Marine Drugs;2024-02-28